Terms: = Endocrine gland cancer AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Treatment
84 results:
1. The application of autofluorescence system contributes to the preservation of parathyroid function during thyroid surgery.
Shi X; Lv G; Qin J; Li Y; Zheng L; Ding H; Sang J
Langenbecks Arch Surg; 2024 Mar; 409(1):96. PubMed ID: 38483607
[TBL] [Abstract] [Full Text] [Related]
2. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract] [Full Text] [Related]
3. Effect of laparoscopic and open distal pancreatectomy on postoperative wound complications in patients with pancreatic cancer: A meta-analysis.
Hong C; Liu W
Int Wound J; 2024 Feb; 21(2):e14708. PubMed ID: 38351522
[TBL] [Abstract] [Full Text] [Related]
4. Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma.
Altieri B; Kimpel O; Megerle F; Detomas M; Chifu I; Fuss CT; Quinkler M; Kroiss M; Fassnacht M
Eur J Endocrinol; 2024 Feb; 190(2):139-150. PubMed ID: 38244214
[TBL] [Abstract] [Full Text] [Related]
5. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
[TBL] [Abstract] [Full Text] [Related]
6. Comparative effectiveness of endoscopic and microscopic adenoma removal in acromegaly.
Vassilyeva N; Mena N; Kirov K; Diatlova E
Front Endocrinol (Lausanne); 2023; 14():1128345. PubMed ID: 37766690
[TBL] [Abstract] [Full Text] [Related]
7. Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study.
Remde H; Schmidt-Pennington L; Reuter M; Landwehr LS; Jensen M; Lahner H; Kimpel O; Altieri B; Laubner K; Schreiner J; Bojunga J; Kircher S; Kunze CA; Pohrt A; Teleanu MV; Hübschmann D; Stenzinger A; Glimm H; Fröhling S; Fassnacht M; Mai K; Kroiss M
Eur J Endocrinol; 2023 Jun; 188(6):485-493. PubMed ID: 37260092
[TBL] [Abstract] [Full Text] [Related]
8. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to treatment.
Burman P; Casar-Borota O; Perez-Rivas LG; Dekkers OM
J Clin Endocrinol Metab; 2023 Jun; 108(7):1585-1601. PubMed ID: 36856733
[TBL] [Abstract] [Full Text] [Related]
9. Aggressive versus indolent insulinomas: new clinicopathological insights.
Hackeng WM; Brosens LAA; Dreijerink KMA
Endocr Relat Cancer; 2023 May; 30(5):. PubMed ID: 36779771
[TBL] [Abstract] [Full Text] [Related]
10. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, atrx, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
Heaphy CM; Singhi AD
Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
[TBL] [Abstract] [Full Text] [Related]
11. Five-year relative survival and determinants of excess mortality in patients with head and neck and thyroid cancers: A population-based study from Golestan province, Northern Iran.
Taziki M; Rajaei S; Firouzei G; Hashemzadeh F; Rajabalian M; Mansoury M; Sedaghat S; Ghahraman F; Ghasemi-Kebria F; Weiderpass E; Roshandel G
Cancer Epidemiol; 2022 Oct; 80():102247. PubMed ID: 36081275
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.
Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM
Surg Pathol Clin; 2022 Sep; 15(3):541-554. PubMed ID: 36049835
[TBL] [Abstract] [Full Text] [Related]
13. Dexamethasone for Postoperative Nausea and Vomiting in Papillary Thyroid Carcinoma Patients: A Randomized Clinical Trial.
Chen W; Li G; Jiang K; Song J; Du R; Yang H; Gou J; Li Z; Zhu J; Lei J
J Am Coll Surg; 2022 Sep; 235(3):454-467. PubMed ID: 35972165
[TBL] [Abstract] [Full Text] [Related]
14. Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M; Mogi K; Kitami K; Uno K; Iyoshi S; Tano S; Fujimoto H; Miyamoto E; Yoshikawa N; Emoto R; Matsui S; Kajiyama H
Int J Clin Oncol; 2022 Oct; 27(10):1660-1668. PubMed ID: 35906336
[TBL] [Abstract] [Full Text] [Related]
15. The diagnostic and prognostic utility of incorporating DAXX, atrx, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract] [Full Text] [Related]
16. A novel tool for predicting the risk of central lymph node metastasis in patients with papillary thyroid microcarcinoma: a retrospective cohort study.
Luo QW; Gao S; Lv X; Li SJ; Wang BF; Han QQ; Wang YP; Guan QL; Gong T
BMC Cancer; 2022 Jun; 22(1):606. PubMed ID: 35655253
[TBL] [Abstract] [Full Text] [Related]
17. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic cancer InterGroup-Symptom Benefit Study.
Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky MC; Diamante K; Stockler MR; Friedlander ML;
Int J Gynecol Cancer; 2022 Jun; 32(6):761-768. PubMed ID: 35086926
[TBL] [Abstract] [Full Text] [Related]
18. Accurate Nodal Staging in Pancreatic cancer in the Era of Neoadjuvant Therapy.
Javed AA; Ding D; Baig E; Wright MJ; Teinor JA; Mansoor D; Thompson E; Hruban RH; Narang A; Burns WR; Burkhart RA; Lafaro K; Weiss MJ; Cameron JL; Wolfgang CL; He J
World J Surg; 2022 Mar; 46(3):667-677. PubMed ID: 34994834
[TBL] [Abstract] [Full Text] [Related]
19. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
[TBL] [Abstract] [Full Text] [Related]
20. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [
Inaki A; Shiga T; Tsushima Y; Jinguji M; Wakabayashi H; Kayano D; Akatani N; Yamase T; Kunita Y; Watanabe S; Hiromasa T; Mori H; Hirata K; Watanabe S; Higuchi T; Tomonaga H; Kinuya S
Ann Nucl Med; 2022 Mar; 36(3):267-278. PubMed ID: 34870794
[TBL] [Abstract] [Full Text] [Related]
[Next]
